Tongwei Zeng,* Yongqiang Xie,* Keqiang Chai, Hui Sang

Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Baiyin, 730900, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hui Sang; Keqiang Chai, Department of Urology, The Third Affiliated Hospital of Gansu University of Traditional Chinese Medicine, No. 222, Silong Road, Baiyin District, Baiyin City, Gansu Province, People’s Republic of China, Email 13830006058@163.com; 312306379@qq.com

Abstract: In recent years, the incidence of prostate cancer has been increasing globally. Early stage of the disease can obtain a better clinical prognosis from surgery and endocrine therapy. The progression of advanced stage varies significantly between individuals, with some patients developing metastatic castration-resistant prostate cancer after standardized treatment. Therefore, staging of prostate cancer by accurate imaging is particularly important for the clinical management of patients. Simultaneously, the development of targeted therapy is also urgent for the treatment of advanced prostate cancer. Prostate specific membrane antigen as a prostate specific target has been widely used in the diagnosis and treatment of prostate cancer. This review summarizes the latest research progress of targeted prostate specific membrane antigen in the diagnosis and treatment of prostate cancer in detail, analyzes their value and challenges.

Keywords: prostate cancer, PSMA, PET, radioligand therapy, CAR-T, DCs vaccine